Exenatide - Qrono
Alternative Names: Exenatide Qx; QR 108Latest Information Update: 28 Sep 2021
At a glance
- Originator Qrono
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Endocrine disorders
Highest Development Phases
- No development reported Endocrine disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Endocrine-disorders in USA (Parenteral, Injection)
- 03 Aug 2017 Exenatide- Qrono is available for licensing as of 03 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)
- 03 Aug 2017 Early research in Endocrine disorders in USA (Parenteral) before August 2017 (Qrono pipeline, August 2017)